350 Afleveringen

  1. 248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

    Gepubliceerd: 2-3-2023
  2. 247: Vertex vs. insurers, Moderna's future, & biotech's long winter

    Gepubliceerd: 23-2-2023
  3. 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid

    Gepubliceerd: 16-2-2023
  4. 245: The return of bird flu and the effects of pandemic fatigue

    Gepubliceerd: 9-2-2023
  5. 244: Pharma blockbusters, pandemic policy, & legal chicanery

    Gepubliceerd: 2-2-2023
  6. 243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection

    Gepubliceerd: 26-1-2023
  7. 242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score

    Gepubliceerd: 19-1-2023
  8. 241: #JPM23 in review, the year ahead, & the merits of Miami

    Gepubliceerd: 12-1-2023
  9. 240: #JPM23, the future of Alzheimer's, & rising Covid variants

    Gepubliceerd: 5-1-2023
  10. 239: 2022 in review, CEO indictments, & the year ahead

    Gepubliceerd: 22-12-2022
  11. 238: Leaky health data, ASH22, & what it takes to get booed by your peers

    Gepubliceerd: 15-12-2022
  12. 237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

    Gepubliceerd: 8-12-2022
  13. 236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

    Gepubliceerd: 1-12-2022
  14. 235: LIVE from the STAT Summit

    Gepubliceerd: 17-11-2022
  15. 234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

    Gepubliceerd: 10-11-2022
  16. 233: How the biotech revolution could come apart at the seams

    Gepubliceerd: 3-11-2022
  17. 232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

    Gepubliceerd: 27-10-2022
  18. 231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market

    Gepubliceerd: 20-10-2022
  19. 230: BIO's messy transition, mRNA's future, & Biogen's next CEO

    Gepubliceerd: 13-10-2022
  20. 229: Nobels for science, biotech dealmaking, & a friendly FTC

    Gepubliceerd: 6-10-2022

6 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site